Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Rini Brian I.; Powles Thomas; Atkins Michael B.; Escudier Bernard; McDermott David F.; Suarez Cristina; Bracarda Sergio; Stadler Walter M.; Donskov Frede; Lee Jae Lyun; Hawkins Robert; Ravaud Alain; Alekseev Boris; Staehler Michael; Uemura Motohide; De Giorgi Ugo; Mellado Begona; Porta Camillo; Melichar Bohuslav; Gurney Howard; Bedke Jens; Choueiri Toni K.; Parnis Francis; Khaznadar Tarik; Thobhani Alpa; Li Shi; Piault-Louis Elisabeth; Frantz Gretchen; Huseni Mahrukh; Schiff Christina; Green Marjorie C.; Motzer Robert J.

首页> 外文期刊>The Lancet >Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

【24h】

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

机译：atezolizumab加贝伐单抗与苏替尼患者以前未经处理的转移性肾细胞癌（Immotion151）：多期，开放标签，第3阶段，随机对照试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background A phase 2 trial showed improved progression-free survival for atezolizumab plus bevacizumab versus sunitinib in patients with metastatic renal cell carcinoma who express programmed death-ligand 1 (PD-L1). Here, we report results of IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab versus sunitinib in first-line metastatic renal cell carcinoma.

机译：背景技术第2期试验显示出于表达编程死亡配体1（PD-L1）的转移性肾细胞癌患者的atezolizumab加贝伐单抗的无进展生存。在此，我们报告Immotion151的结果，将Atezolizumab加贝伐单抗与仙岛在一线转移性肾细胞癌中的eventumab相比进行了评估。

著录项

来源
《The Lancet》 |2019年第10189期|共12页
作者
Rini Brian I.; Powles Thomas; Atkins Michael B.; Escudier Bernard; McDermott David F.; Suarez Cristina; Bracarda Sergio; Stadler Walter M.; Donskov Frede; Lee Jae Lyun; Hawkins Robert; Ravaud Alain; Alekseev Boris; Staehler Michael; Uemura Motohide; De Giorgi Ugo; Mellado Begona; Porta Camillo; Melichar Bohuslav; Gurney Howard; Bedke Jens; Choueiri Toni K.; Parnis Francis; Khaznadar Tarik; Thobhani Alpa; Li Shi; Piault-Louis Elisabeth; Frantz Gretchen; Huseni Mahrukh; Schiff Christina; Green Marjorie C.; Motzer Robert J.;
展开▼
作者单位

Cleveland Clin Taussig Canc Inst Cleveland OH 44106 USA;

Queen Mary Univ London Barts Canc Inst London England;

Georgetown Lombardi Comprehens Canc Ctr Washington DC USA;

Gustave Roussy Villejuif France;

Beth Israel Deaconess Med Ctr Boston MA 02215 USA;

Univ Autonoma Barcelona Vall dHebron Univ Hosp Vall dHebron Inst Oncol Barcelona Spain;

Azienda Osped S Maria Terni Italy;

Univ Chicago Med Chicago IL USA;

Aarhus Univ Hosp Dept Oncol Aarhus Denmark;

Univ Ulsan Coll Med Asan Med Ctr Dept Oncol Seoul South Korea;

Christie NHS Fdn Trust Manchester Lancs England;

CHU Hop Bordeaux Hop St Andre Bordeaux France;

P Herzen Oncol Res Inst Moscow Russia;

Klinikum Univ Munchen Campus Grosshadern Munich Germany;

Osaka Univ Dept Urol Grad Sch Med Osaka Japan;

IRCCS Ist Sci Romagnolo Studio &

Cura Tumori Meldola Italy;

Hosp Clin Barcelona Inst Invest Biomed August Pi &

Sunyer Barcelona Spain;

IRCCS San Matteo Univ Hosp Fdn Pavia Italy;

Univ Palackeho Lekarska Fak Olomouc Czech Republic;

Macquarie Univ Dept Clin Med Sydney NSW Australia;

Univ Tubingen Dept Urol Tubingen Germany;

Dana Farber Canc Inst Boston MA 02115 USA;

Ashford Canc Ctr Res Kurralta Pk SA Australia;

F Hoffmann La Roche Basel Switzerland;

Roche Prod Ltd Welwyn Garden City Herts England;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial [J] . Rini Brian I., Powles Thomas, Atkins Michael B., The Lancet . 2019,第10189期

机译：atezolizumab加贝伐单抗与苏替尼患者以前未经处理的转移性肾细胞癌（Immotion151）：多期，开放标签，第3阶段，随机对照试验
2. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial [J] . Rini Brian I., Stenzl Arnulf, Zdrojowy Romauld, The lancet oncology . 2016,第11期

机译：IMA901，一种多肽类癌症疫苗，加舒尼替尼与单独舒尼替尼比较，作为晚期或转移性肾细胞癌（IMPRINT）的一线治疗：一项多中心，开放标签，随机，对照，3期试验
3. Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial [J] . Armstrong Andrew J., Halabi Susan, Eisen Tim, The lancet oncology . 2016,第3期

机译：依维莫司与舒尼替尼治疗转移性非透明细胞肾细胞癌（ASPEN）患者：一项多中心，开放标签，随机2期试验
4. Designing Phase III Trials in Metastatic Renal Cell Carcinoma: What Are the New Standards? [C] . Ana M. Molina Genitourinary Cancers Symposium . 2012

机译：在转移性肾细胞癌中设计III期试验：新标准是什么？
5. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
6. Open-label randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial [O] . Guillaume Mouillet, Marie-Justine Paillard, Tristan Maurina, 2018

机译：开放标签随机多中心II期研究通过剂量给药方案（剂量修改或剂量中断）评估舒尼替尼在晚期或转移性肾细胞癌患者中的疗效和耐受性：SURF试验的研究方案
7. Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma [O] . Michael B. Atkins, Brian I. Rini, Robert J. Motzer, 2020

机译：患者报告的结果来自第3阶段随机的Immotion151试验：Atezolizuab + Bevacizumab与治疗幼稚转移性肾细胞癌的孙

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

摘要

著录项

相似文献

相关主题

期刊订阅